Stock Taper
Sight Sciences, Inc. develops and commercializes surgical and nonsurgical eye disease treatment devices, including the OMNI Surgical System and TearCare System, serving ophthalmologists and optometrists in the U.S. since 2010.

The OMNI Edge Surgical System is a single-use, handheld device for minimally invasive glaucoma surgery that reduces intraocular pressure by targeting all resistance points, enhancing Sight Sciences' implant-free glaucoma treatment options.
| Icon | PRODUCT | Q3-2025 | Q4-2025 | Q1-2026 | Q2-2026 |
|---|---|---|---|---|---|
![]() | Surgical Glaucoma | $19.72M | $19.66M ▼ | $18.34M ▼ | $20.71M ▲ |
![]() | Dry Eye | $188K | $724K ▲ | $1.35M ▲ | $2.67M ▲ |
Overall rating: C-
| PEER | PRICE | |
|---|---|---|
CERS | $2.65 | COMPARE |
MASS | $10.73 | COMPARE |
SENS | $9.33 | COMPARE |
VMD | $8.82 | COMPARE |
PRQR | $2.29 | COMPARE |
LFCR | $4.54 | COMPARE |
QTRX | $2.64 | COMPARE |
CVRX | $2.95 | COMPARE |